#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Perspectives in Surgery / 2023 - 9

Surgical therapy of chronic lung allograft dysfunction

Česká verzia

Authors: R. Novysedlák 1*;  J. Tavandžis 1*;  J. Balko 2;  Z. Ozaniak Střížová 3;  J. Vachtenheim Jr 1;  R. Lischke 1
Authors place of work: Tito autoři se na této práci podíleli stejným dílem *;  Národní program transplantace plic pro Českou a Slovenskou republiku, III. chirurgická klinika 1. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice v Motole, Praha, Česká republika 1;  Ústav patologie a molekulární medicíny 2. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice v Motole, Praha, Česká republika 2;  Ústav imunologie 2. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice v Motole, Praha, Česká republika 3
Published in the journal: Rozhl. Chir., 2023, roč. 102, č. 9, s. 345-351.
Category: Review
doi: https://doi.org/10.33699/PIS.2023.102.9.345–351

Summary

Lung transplantation has become a standardized and widely accepted treatment modality for selected end-stage lung diseases. Many factors influ- ence the long-term survival of patients after lung transplantation. One of the most important is clearly the development of chronic lung allograft dysfunction (CLAD). This review summarizes current knowledge of the histopathology of CLAD and its clinical characteristics. It also describes lung re-transplantation as the only causal therapy, its possible complications, and outcomes in standard and high-urgency patients awaiting a suitable organ with extracorporeal membrane oxygenation support. Fundoplication is an important surgical modality potentially leading to an improvement of the patients’ condition. The indications and outcomes of this surgical procedure are discussed in a separate chapter. In addition, several nonsurgical treatment options aimed at slowing the progression of CLAD are outlined, as well as ongoing research focused on extending the life of these patients.

Keywords:

Lung transplantation – lung retransplantation – chronic lung allograft dysfunction – fundoplication for CLAD

Zdroje
  1. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment. A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493−503. doi:10.1016/j.healun 2019.03.009.
  2. Verleden GM, Raghu G, Meyer KC, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant.2014;33(2):127−133. doi:10.1016/j.healun.2013.10.022.
  3. Bos S, Vos R, Van Raemdonck DE, et al. Survival in adult lung transplantation: where are we in 2020? Curr Opin Organ Transplant. 2020;25(3):268−273. doi:10.1097/MOT.0000000000000753.
  4. Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385(8):729−743. doi:10.1056/NEJMra2014530.
  5. DerHovanessian A, Wallace WD, Lynch JP 3rd, et al. Chronic lung allograft dysfunction: evolving concepts and therapies. Semin Respir Crit Care Med. 2018;39(2):155−171. doi:10.1055/s-0037-1618567.
  6. Verleden SE, Vos R, Vanaudenaerde BM, et al. Chronic lung allograft dysfunction phenotypes and treatment. J Thorac Dis. 2017;9(8):2650−2659. doi:10.21037/ jtd.2017.07.81.
  7. Silva T, Voisey J, Hopkins P, et al. Markers of rejection of a lung allograft: state of the art. Biomark Med. 2022;16(6):483−498. doi:10.2217/bmm-2021-1013.
  8. Kneidinger N, Ghiani A, Milger K, et al. Impact of lung function decline on mortality in lung transplant recipients: Long-term results from the L-CsA-i study for the prevention of bronchiolitis obliterans syndrome. Front Med. (Lausanne) 2022;9:897581. doi:10.3389/fmed. 2022.897581.
  9. Amubieya O, Ramsey A, DerHovanessian A, et al. Chronic lung allograft dysfunction: evolving concepts and therapies. Semin Respir Crit Care Med.2021;42(3):392−410. doi:10.1055/s-0041-1729175.
  10. Michel E, Galen Hartwig M, Sommer W. Lung retransplantation. Thorac Surg Clin. 2022;32(2):259−268. doi:10.1016/j.thorsurg.2021.12.001.
  11. Rucker AJ, Nellis JR, Klapper JA, et al. Lung retransplantation in the modern era. J Thorac Dis. 2021;13(11):6587–6593. doi:10.21037/jtd-2021-25.
  12. Godinas L, Van Raemdonck D, Ceulemans LJ, et al. Lung retransplantation: walking a thin line between hope and false expectations. J Thorac Dis.2019;11(11):E200− E203. doi:10.21037/jtd.2019.11.02.
  13. Miller JD, Patterson GA. Retransplantation following isolated lung transplantation. Semin Thorac Cardiovasc Surg. 1992;4(2):122−125.
  14. Fournier M, Sleiman C, Mal H, et al. Single-lung retransplantation for late graft failure. Eur Respir J. 1993;6(8):1202−1206.
  15. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44(6):1479−1503.  doi:10.1183/09031936.00107514.
  16. Sato M, Hwang DM, Ohmori-Matsuda K, et al. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. J Heart Lung Trans-plant. 2012;31(4):354−363. doi:10.1016/j. healun.2011.12.015.
  17. Todd JL, Jain R, Pavlisko EN, et al. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am JRespir Crit Care Med. 2014;189(2):159−166. doi:10.1164/rccm. 201306-1155OC.
  18. Glanville AR, Verleden GM, Todd JL, et al. Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome. Aconsensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):483−492. doi:10.1016/j.healun.2019.03.008.
  19. Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis.Mod Pathol. 2013;26(3):350−356. doi:10.1038/modpathol.2012.171.
  20. von der Thusen JH, Vandermeulen E, Vos R, et al. The histomorphological spectrum of restrictive chronic lung allograft dysfunction andimplications for prognosis. Mod Pathol. 2018;31(5):780−790. doi:10.1038/modpathol.2017.180.
  21. Harhay MO, Cherikh WS, Toll AE, et al. Epidemiology, risk factors, and outcomes of lung retransplantation: An analysis of the InternationalSociety for Heart and Lung Transplantation Thoracic Transplant Registry. J Heart Lung Transplant. 2022;41(10):1478−1486. doi:10.1016/j.healun.2022.06.022.
  22. Biswas Roy S, Panchanathan R, Walia R, et al. Lung retransplantation for chronic rejection: A single-center experience. Ann Thorac Surg.2018;105(1):221−227.doi:10.1016/j.athoracsur.2017.07.025.
  23. Halloran K, Aversa M, Tinckam K, et al. Comprehensive outcomes after lung retransplantation: A single-center review. Clin Transplant.2018;32(6):e13281. doi:10.1111/ctr.13281.
  24. Verleden SE, Todd JL, Sato M, et al. Impact of CLAD phenotype on survival after lung retransplantation: A multicenter study. Am J Transplant.2015;15(8):2223−2230.doi:10.1111/ajt.13281.
  25. Abdelnour-Berchtold E, Federici S, Wurlod DA, et al. Outcome after extracorporeal membrane oxygenation-bridged lung retransplants: a single-centre experience. Interact Cardiovasc Thorac Surg. 2019;28(6):922−928. doi:10.1093/icvts/ivz013.
  26. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med. 2008;177(1):114−120. doi:10.1164/ rccm.200707-1132OC.
  27. Wallinder A, Danielsson C, Magnusson J, et al. Outcomes and long-term survival after pulmonary retransplantation: A single-centerexperience. Ann Thorac Surg. 2019;108(4):1037−1044.doi:10.1016/j.athoracsur.2019.04.028.
  28. Osaki S, Maloney JD, Meyer KC, et al. Redo lung transplantation for acute and chronic lung allograft failure: long-term follow-up in a singlecenter. Eur J Cardiothorac Surg. 2008;34(6):1191−1197. doi:10.1016/j.ejcts.2008.07.052.
  29. Ganapathi AM, Heh V, Rosenheck JP, et al. Thoracic retransplantation: Does time to retransplantation matter? J Thorac Cardiovasc Surg. 2022 May 15;S0022−5223. doi:10.1016/j.jtcvs.2022.05.003.
  30. Fessler J, Glorion M, Finet M, et al. Perioperative outcomes during double-lung transplantation and retransplantation in cystic fibrosispatients: A monocentric cohort study. J Cardiothorac Vasc Anesth. 2023;37(6):964−971. doi:10.1053/j.jvca.2023.02.029.
  31. Dubey GK, Hossain A, Dobrescu C, et al. Repeat lung retransplantation and death risk. J Heart Lung Transplant. 2020;39(8):841−845.doi:10.1016/j.healun.2020.05.008.
  32. Zhang M, SecoAntunes AR, Kessler R, et al. Multiple lung transplant in a patient within 25 years: A case report. Exp Clin Transplant. 2020;18(2):265−266. doi:10.6002/ect.2018.0340.
  33. Vakil N, Mason DP, Yun JJ, et al. Third-time lung transplantation in a patient with cystic fibrosis. J Thorac Cardiovasc Surg. 2011;141(1):e3−5. doi:10.1016/j. jtcvs.2010.09.028.
  34. Keshavjee S. Retransplantation of the lung comes of age. J Thorac Cardiovasc Surg. 2006;132(2):226−228. doi:10.1016/j. jtcvs.2006.04.005.
  35. D’Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg. 2005;129(5):1144−1152. doi:10.1016/j.jtcvs.2004.10.035.
  36. Mertens V, Blondeau K, Van Oudenhove L, et al. Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin. Am JTransplant. 2011;11(2):329−335. doi:10.1111/j.1600-6143.2010.03380.x.
  37. Blondeau K, Mertens V, Vanaudenaerde BA, et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J. 2008;31(4):707−713. doi:10.1183/09031936.00064807.
  38. Hadjiliadis D, Duane Davis R, Steele MP, et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant. 2003;17(4):363−368. doi:10.1034/ j.1399-0012.2003.00060.x.
  39. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J ThoracCardiovasc Surg. 2007;133(4):1078−1084.doi:10.1016/j.jtcvs.2006.09.085.
  40. Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac CardiovascSurg. 2006;131(2):438−446. doi:10.1016/j.jtcvs.2005.10.014.
  41. Benden C, Aurora P, Curry J, et al. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol. 2005;40(1):68−71. doi:10.1002/ppul.20234.
  42. Davis RD Jr., Lau CL, Eubanks S, et al.Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. JThorac Cardiovasc Surg. 2003;125(3):533−542. doi:10.1067/ mtc.2003.166.
  43. Cantu E, 3rd, Appel JZ, 3rd, Hartwig MG, et al. J. Maxwell Chamberlain memorial paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78(4): 1142−1151; discussion 1142–1151. doi: 10.1016/j.athoracsur.2004.04.044.
  44. Biswas RS, Elnahas S, Serrone R, et al. Early fundoplication is associated with slower decline in lung function after lung transplantation inpatients with gastroesophageal reflux disease. J Thorac Cardiovasc Surg. 2018;155(6):2762−2771 e2761. doi:10.1016/j.jtcvs.2018.02.009.
  45. Razia D, Mittal SK, Bremner RM, et al. Pretransplant GERD-induced immune response predisposes to CLAD. The Journal of Heart and Lung Transplantation 2021;40(4). doi:10.1016/j. healun.2021.01.1884.
  46. Lo WK, Moniodis A, Goldberg HJ, et al. Increased acid exposure on pretransplant impedance-pH testing is associated with chronic rejection after lung transplantation. Journal of Clinical Gastroenterology 2020;54(6):517−521. doi:10.1097/ mcg.0000000000001331.
  47. Davidson JR, Franklin D, Kumar S, et al. Fundoplication to preserve allograft function after lung transplant: Systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2020;160(3):858−866. doi:10.1016/j.jtcvs.2019.10.185.
  48. Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux disease. StatPearls 2023.
  49. Frazzoni M, Piccoli M, Conigliaro R, et al. Laparoscopic fundoplication for gastro-esophageal reflux disease. World J Gastroenterol. 2014;20(39):14272−14279. doi: 10.3748/wjg.v20.i39.14272.
  50. D’Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg. 2005;80(4):1254−1260. doi:10.1016/j.atho-racsur.2005.03.106.

(Další odkazy na literaturu jsou dostupné ve webové verzi článku na www.perspinsurg.com).

MUDr. René Novysedlák
Národní program transplantace plic
pro Českou a Slovenskou republiku
III. chirurgická klinika 1. LF UK a FN v Motole
e-mail: rene.novysedlak@fnmotol.cz
ORCID: 0000-0002-2660-6815

Štítky
Surgery Orthopaedics Trauma surgery
Článek Gastarbeiter’s look back (or a handful of observations for those interested in professional exile)
Článek Treatment of the congenital thoracic deformity pectus excavatum
Článek Blood loss during HPB procedures
Článek Triple neurectomy following Lichtenstein repair of inguinal hernia
Článek Giant peritoneal loose body – case report
Článok vyšiel v časopise

Perspectives in Surgery

Číslo 9
2023 Číslo 9
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#